



**Wilson, Chelsey and Bushell, Trevor and Jiang, Hui-Rong (2016)
Expression of IL-22 and IL-22R1 subunit in the central nervous system of
experimental autoimmune encephalomyelitis mice. In: BSI/NVVI
congress 2016, 2016-12-06 - 2016-12-09, ACC. ,**

This version is available at <https://strathprints.strath.ac.uk/61004/>

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (<https://strathprints.strath.ac.uk/>) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk

Introduction

Background

Interleukin (IL)-22, a T-helper (Th)-17 linked cytokine, has been associated with several autoimmune diseases. However, the role of IL-22 in multiple sclerosis (MS) has still be elucidated¹.

While IL-22 is believed to aid in lymphocyte infiltration² of the CNS and elevated levels were observed in serum and lesion of MS patients, studies have highlighted potentially protective functions³ within MS and experimental autoimmune encephalomyelitis (EAE) – an animal model of MS.

Aim

This study aims to characterise the expression of IL-22 and its receptor subunit IL-22R1 in normal and EAE CNS tissue, and examine any potential correlation between expression level and disease severity.


Methods

EAE Induction

- C57BL/6 female mice were immunised subcutaneously with MOG₃₅₋₅₅ peptide or vehicle emulsified in complete Freund's adjuvant.
- Mice were weighed daily and scored based on tail/leg paralysis.

Immunohistochemistry

- Immunohistochemistry was used to determine IL-22 (Abcam; ab18499) and IL-22R1 (R&D; MAB42941) expression and co-localisation with CNS resident cells and infiltrating immune cells.



Results




Figure 1 MOG induced EAE follows a monophasic disease course: Following immunisation, mice were scored daily. Clinical scores expressed as an average \pm S.E.M. EAE, n=6-39; PBS, n=6-23. **P<0.005, ***P<0.001 versus PBS




Figure 2 Serum expression of IL-22 correlates with EAE disease progression: Serum expression of IL-22 was determined by ELISA. EAE, n=6; PBS, n=5. **P<0.01, ***P<0.001 versus PBS, #P<0.05 versus EAE onset, ###P<0.001 versus EAE peak.




Figure 3 IL-22 expression in spinal correlates with EAE disease progression: Spinal cord sections were stained for expression of IL-22. Expression quantified using ImageJ. n=6 for all groups. **P<0.01, ***P<0.001 versus PBS control.





Figure 4 IL-22 co-localises with neurons and astrocytes: Double fluorescence staining was used to determine co-localisation of IL-22 with neurons and astrocytes. Expression quantified using ImageJ. n=6 for all groups. Scale bar= 100 μ m. ***P <0.001 versus naive.




Figure 5 IL-22 co-localises with several immune cells. Double fluorescence staining was used to determine co-localisation of IL-22 with various infiltrating immune cells. All sections used were peak EAE. Expression quantified using ImageJ. n=5 for each group. Scale bar= 50 μ m.




Figure 6 IL-22R1 expression in spinal cord is elevated during EAE within white matter and lesion areas: Spinal cord sections were stained for expression of IL-22R1. Expression quantified using ImageJ. n=6 for all groups. *P<0.05, **P<0.01, ***P<0.001 versus PBS control.





Figure 7 IL-22R1 co-localises with neurons and astrocytes: Double fluorescence staining was used to determine co-localisation of IL-22R1 with neurons and astrocytes. Expression quantified using ImageJ. n=3 for all groups. Scale bar= 100 μ m.

Reference

- Dudakov *et al.*, 2015. *Annu Rev Immunol.* 33: 747-85
- Keber *et al.*, 2007. *Nature Med.* 13: 1173-75
- Perriard *et al.*, 2015. *J. Neuroinflamm.* 12: 119 - 26

Acknowledgments

Funding for this project was provided by the BBSRC

Contact Details

If you have any further questions Please email me at chelsey.wilson@strath.ac.uk

Conclusion

Our data shows that:

- Serum IL-22 elevated during EAE in a similar manner to MS patients during active disease.³
- IL-22 and IL-22R1 expression elevated in EAE spinal cord tissue, particularly within proximity of inflammatory lesions.
- Neurons express comparable levels of IL-22 and IL-22R1 in naïve and EAE mice however astrocytic expression of both is elevated during EAE specifically within the inflammatory lesions.
- Our data suggests IL-22 plays an important role in the development and progression of CNS inflammation however whether this function is mediated through astrocytes or other means has still to be determined.